Q2 2022 Ocular Therapeutix, Inc. Earnings Conference Call
Monday, August 08, 2022 4:30 PM EDT
Ocular Therapeutix, Inc. at the Jefferies Healthcare Conference
Wednesday, June 08, 2022 8:00 AM EDT

Corporate Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has received a target action date under the Prescription Drug User Fee Act, commonly known as PDUFA, of October 18, 2021, for a supplemental new drug application for DEXTENZA to include an additional indication for the treatment of ocular itching associated with allergic conjunctivitis...

(Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.